Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain

Lindsay A. Welikovitch\textsuperscript{a}, Sonia Do Carmo\textsuperscript{a}, Zsófia Maglóczky\textsuperscript{b}, Janice C. Malcolm\textsuperscript{d}, János Lőke\textsuperscript{e}, William L. Klein\textsuperscript{f}, Tamás Freund\textsuperscript{g}, and A. Claudio Cuello\textsuperscript{a,b,d,h,1}

\textsuperscript{a}Department of Neurology and Neurosurgery, McGill University, Montreal, QC H3G 1Y6, Canada; \textsuperscript{b}Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada; \textsuperscript{c}Human Brain Research Laboratory, Institute of Experimental Medicine of the Hungarian Academy of Sciences, 1051 Budapest, Hungary; \textsuperscript{d}Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3G 1Y6, Canada; \textsuperscript{e}Department of Psychiatry, Szent Borbála Hospital, 2800 Tatabánya, Hungary; \textsuperscript{f}Department of Neurobiology, Northwestern University, Evanston, IL 60208; \textsuperscript{g}Laboratory of Cerebral Cortex Research, Institute of Experimental Medicine of the Hungarian Academy of Sciences, 1051 Budapest, Hungary; and \textsuperscript{h}Department of Pharmacology, University of Oxford, OX1 2JD Oxford, Oxford, United Kingdom

Chronic inflammation during Alzheimer’s disease (AD) is most often attributed to sustained microglial activation in response to amyloid-\(\beta\) (A\(\beta\)) plaque deposits and cell death. However, cytokine release and microglial activation are consistently observed in AD transgenic animal models devoid of such pathologies, bringing into question the underlying processes that may be at play during the earliest AD-related immune response. We propose that this plaque-independent inflammatory reaction originates from neurons burdened with increasing levels of soluble and oligomeric A\(\beta\), which are known to be the most toxic amyloid species within the brain. Laser microdissected neurons extracted from preplaque amyloid precursor protein (APP) transgenic rats were found to produce a variety of potent immune factors, both at the transcript and protein levels. Neuron-derived cytokines correlated with the extent of microglial activation and mobilization, even in the absence of extracellular plaques and cell death. Importantly, we identified an inflammatory profile unique to A\(\beta\)-burdened neurons, since neighboring glial cells did not express similar molecules. Moreover, we demonstrate within disease-vulnerable regions of the human brain that a neuron-specific inflammatory response may precede insoluble A\(\beta\) plaque and tau tangle formation. Thus, we reveal the A\(\beta\)-burdened neuron as a primary proinflammatory agent, implicating the intraneuronal accumulation of A\(\beta\) as a significant immunological component in the AD pathogenesis.

Intraneuronal A\(\beta\) | neuronal inflammation | preplaque pathology | Alzheimer’s disease

Neuroinflammation in Alzheimer’s disease (AD) has classically been regarded as a glial- and plaque-driven phenomenon: Activated microglia become coordinately recruited toward extracellular amyloid-\(\beta\) (A\(\beta\)) plaques, releasing toxic proinflammatory molecules and inciting neuronal damage (1–4). This overt inflammatory reaction was initially characterized as a secondary effect of advanced plaque deposition and ongoing neurodegeneration. However, reports from numerous epidemiological studies have since demonstrated that long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) in patients with rheumatoid arthritis lowers the risk of developing AD (5), suggesting that inflammation may in fact be an earlier component of the AD continuum than previously thought. Despite initial indications, clinical trials on the use of NSAIDs in already-diagnosed AD patients were found to be ineffective at slowing disease progression, and in some cases, even worsened clinical outcomes (6, 7). These contradictory findings have prompted the field to reexamine established hypotheses on the role of neuroinflammation in AD, which is now believed to be a dynamic and phase-dependent process (8, 9). During early, prodromal disease stages, neuroinflammation is likely a pathological accelerator, the effects of which can be mitigated by chronic NSAID use (9, 10). In contrast, neuroinflammation during late disease stages is likely associated with clearance of neural debris and A\(\beta\) plaques by phagocytic macrophages, and tissue resolution (8). Inhibiting these protective mechanisms in symptomatic patients with substantial neurodegeneration and established neuropathologies would likely have little benefit. As a result, understanding the earliest cellular processes that drive neuroinflammation during AD will be crucial in establishing therapeutic strategies aimed at derailing the disease trajectory, before the brain is affected beyond rescue.

Prior to the formation of extracellular plaques and tau neurofibrillary tangles (NFT), A\(\beta\) peptides and oligomers appear to accumulate within neurons of disease-vulnerable brain regions (11–15). This soluble pool of intraneuronal A\(\beta\) (iA\(\beta\)) also increases in an age-dependent manner within the entorhinal cortex, a brain region regarded as the origin of AD neuropathological spread (13, 15). Despite the fact that A\(\beta\) oligomers represent the most toxic amyloid species within the brain (16–20), the effects of progressive iA\(\beta\) build-up have scarcely been studied, and information on how this soluble pool may influence AD susceptibility is lacking.

Studies in several transgenic animal models of AD have consistently demonstrated that iA\(\beta\) accumulation in the absence of plaque and tau pathologies is sufficient to produce synaptic abnormalities (21), long-term potentiation (LTP) impairment (21–24), and cognitive deficits (25–31), suggesting that the earliest

**Significance**

This work provides evidence that soluble and oligomeric amyloid protein stokes neuronal inflammation during the earliest stages of Alzheimer’s disease. Identifying neuron-derived factors that engage the brain’s immune system will provide insight into how vulnerable neurons might interact with other immune cells to propagate cytotoxic signaling cascades and cellular dysfunction during disease development.

Author contributions: L.A.W., S.D.C., and A.C.C. designed research; L.A.W., S.D.C., Z.M., J.C.M., and J.L. performed research; Z.M., J.L., W.L.K., and T.F. contributed new reagents/analytic tools; L.A.W., S.D.C., and J.C.M. analyzed data; and L.A.W., S.D.C., and A.C.C. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

To whom correspondence may be addressed. Email: claudio.cuello@mcgill.ca.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1914593117/-/DCSupplemental.

First published March 6, 2020.
toxic effects of Aβ may in fact begin intraneuronally. Our laboratory and others have also shown that proinflammatory cytokines and chemokines become up-regulated within the brains of these animals months before initial plaque deposition and in the absence of cell loss (22, 32–38).

Despite the fact that Aβ accumulation is restricted to the intracellular space during this preplaque phase, the root cause of the corresponding neuroinflammatory response has yet to be identified. We therefore hypothesized that the Aβ-burdened neuron represents a primary proinflammatory agent during the earliest stages of the amyloid pathology, independent of extracellular plaques and cell death.

Using the McGill-R-Thy1-APP transgenic rat, which expresses the mutated human amyloid precursor protein (APP) gene, we extracted Aβ-burdened hippocampal neurons by laser-capture microdissection (LCM) and analyzed the effects of iAβ build-up on neuronal inflammatory gene expression. We demonstrate that key inflammatory mediators are up-regulated by neurons in preplaque APP transgenic rats, both at the transcript and protein levels, and that this inflammatory signal correlates with the localized recruitment of activated microglia. We also propose that a similar neuron-specific response may precede extracellular plaque deposition and pathological NFT formation within the human brain. Our findings suggest that progressive iAβ build-up undermines a neuron-driven inflammatory process, triggering complex neuroimmune interactions at the outset of the AD neuropathological cascade.

Results

Aβ-Burdened Neurons Are Inflamed in Preplaque APP Transgenic Rats.

To determine the effects of iAβ accumulation on neuronal inflammatory gene expression, neurons were extracted from the hippocampus of 5-mo-old wild-type (WT) and preplaque APP transgenic (Tg) rats by LCM and subjected to qRT-PCR. At 5 mo of age, the McGill-R-Thy1-APP rat exhibits significant accumulation of iAβ peptides and oligomers in the subiculum, CA1, CA3, and all cortical layers, as revealed by McSA1- and NU-1-immunolabeling, respectively (Fig. 1). Extracellular plaques are not observed in this animal model until 9 mo of age (30).

The pyramidal layer of the subiculum and CA1 was precisely excised by LCM to produce neuron-enriched histological samples with minimal glial contamination (Fig. 2A and SI Appendix, Fig. S1). When analyzed by qRT-PCR, levels of neuron-specific MAP2 and TUBB3 were found to be 3.3- and 2.1-fold higher, respectively, in our microdissected samples compared with whole-brain homogenate, validating that we had in fact obtained an enriched sample of neuron-derived mRNA (SI Appendix, Fig. S1C).

Microdissected neurons were then subjected to qRT-PCR using the RT2 Cytokine and Chemokine Profiler PCR Array to measure differential expression of 84 transcripts commonly involved in inflammation and tissue resolution (SI Appendix, Table S1). Following quantitative analyses, we found a statistically significant increase in the expression of several chemotactic factors in Aβ-burdened neurons, including CCL2 (chemokine ligand 2), CCL3 (chemokine ligand 3), and CSF-1 (colony stimulating factor-1) (Fig. 2B). We also detected a statistically significant decrease in the neuronal expression of CAF70 and IL-12a (interleukin-12 subunit alpha) in these same Tg animals.

Next, to assess whether these inflammatory transcripts were similarly altered at the protein level, we performed neuron-specific fluorescence quantification following brain tissue double-immunolabeling. Using a fluorescein-conjugated antibody against NeuN, a highly specific marker for mature neurons, we quantified the fluorescence intensity of immunolabeled-chemokines exclusively within NeuN-immunoreactive (IR) cell bodies (SI Appendix, Fig. S2A). Consistent with our previous results, we found a statistically significant increase in neuronal CCL2 and CCL3 in the subiculum, as well as an increase in neuronal CCL2 in CA1 of our preplaque

Tg rats; CCL3 signal intensity was unchanged in this region (Fig. 3).

Gene-expression analysis of microdissected neurons revealed an interesting trend in the expression of IL-6 (interleukin-6): While neuronal IL-6 was largely undetectable or detected at extremely low levels in most animals, four Tg rats exhibited very high expression levels compared with the control group. This suggested that the amount of tissue isolated by LCM may not have reached the critical mass necessary to reliably detect IL-6 in all samples. Therefore, we decided to measure the relative protein expression of neuronal IL-6 by immunohistochemistry (IHC) in WT and Tg rats. Following fluorescence quantification, we did in fact find a statistically significant increase in neuronal IL-6 in the subiculum and CA1 of these preplaque Tg rats (Fig. 3).
Activated Microglia Are Recruited toward Inflamed Aβ-Burdened Neurons. We have previously observed that microglia become recruited toward hippocampal neurons in APP Tg mice (37) and rats (33, 38). Here, we hypothesized that activated microglia would become recruited toward the hippocampal pyramidal layer, even in the absence of extracellular plaques, in response to proinflammatory mediators produced by Aβ-burdened neurons. We therefore measured the number of microglia in proximity or in direct contact with hippocampal neurons in 5-mo-old WT and preplaque Tg rats. Indeed, we found a statistically significant increase in the number of Iba1-IR cells within 50 μm of the subiculum and CA1 of our Tg animals (Fig. 4A). This appeared to be a localized response, since the total number of microglial cells, as well as the total percent-area of Iba1-IR was found to be unchanged in the regions extending beyond the pyramidal layer (stratum oriens and stratum radiatum).

In response to an inflammatory stimulus, microglia undergo morphological changes that reflect a shift in their activation state. When adopting a “reactive” phenotype, microglia exhibit an increase in cell-body size and retraction of their processes, previously defined as an intermediate activation state (37, 39). This change in morphology can be measured by calculating the microglia dimensional ratio (DR) (SI Appendix, Fig. S2B), whereby an increase in DR is indicative of a shift toward a proinflammatory phenotype. Quantitative analysis revealed that microglia within the hippocampus of preplaque Tg rats did in fact exhibit an increase in DR compared with controls (Fig. 4A).

We also performed Pearson correlation coefficient analyses to determine if there was a relationship between neuronal cytokine expression and microglial reactivity. We found that levels of neuronal CCL2, as measured by quantitative fluorescent IHC, were positively correlated with the number of Iba1-IR cells in close proximity with the pyramidal layer of the hippocampus (Fig. 4B). Levels of neuronal IL-6 were also positively correlated with microglia DR, and thus the extent of microglial activation. Interestingly, this same linear relationship was not supported when neuronal CCL2 was correlated with microglia DR, or when neuronal IL-6 was correlated with microglial recruitment (P > 0.05). These findings indicate that, in this model, neuronal expression of chemotactic CCL2 is more closely related to microglial recruitment, while that of proinflammatory IL-6 is more closely related to microglial activation.

Neuron-Derived Inflammatory Factors Are Not Detected in Glia during the Preplaque Phase of the Aβ Pathology in APP Tg Rats. To assess the cell-specific expression of inflammatory factors found to be up-regulated in Aβ-burdened neurons, we performed double-immunolabeling of brain tissue from preplaque Tg rats using antibodies directed against microglia- and astrocyte-specific cell markers, Iba1 and GFAP, and inflammatory cytokines, CCL2, CCL3, and IL-6 (Fig. 5A and B). No significant colocalization was observed between either glial cell-marker and any of the inflammatory molecules. Neurons were easily identifiable based on their intracellular cytokine immunolabeling, while glia could not be visualized without the use of their cell-specific markers. These results confirm that the up-regulation of CCL2, CCL3, and IL-6 likely represents a neuron-derived inflammatory signal, at least during the earliest stages of the Aβ pathology.

To corroborate our findings from gene expression and IHC analyses, we performed single-molecule RNA FISH, revealing the cell-specific localization of CCL2 transcripts in the hippocampus of 5-mo-old WT and Tg rats (Fig. 5C). Fluorophore-conjugated probes directed against GAPDH were used as a comparative positive control. Hippocampal neurons displayed stronger fluorescence-intensity associated with CCL2 mRNA compared with neighboring glial cells, both in WT and Tg animals; however, this difference in cell-specific expression appeared to be more pronounced in Tg rats. This observation not only confirms that neurons do in fact express appreciable levels of CCL2 mRNA under physiological conditions, but also that, in the context of Aβ pathology, neurons rather than glia produce a potent chemotactic signal through the up-regulation of CCL2 transcription.

Lower Levels of iAβ Are Associated with Milder Inflammation in Young APP Tg Rats. At 5 mo of age, the McGill-R-Thyl-APP rat displays a robust neuron-specific inflammatory reaction and a corresponding microglial response. Given that this animal model exhibits progressive amyloid accumulation with age, we hypothesized that increasing levels of intracellular Aβ would amplify neuronal proinflammatory signaling and intensify the resulting immune response within the brain. Conversely, we were interested in whether those inflammatory processes observed in 5-mo-old Tg

![Fig. 2.](image-url)
rats would be present in even younger animals harboring lower levels of brain Aβ. Employing similar analyses from previous experiments, we evaluated different aspects of neuroinflammation in 2-mo-old Tg rats. At this very early stage of the preplaque pathology, intracellular Aβ is detectable by McSA1 immunolabeling; however, iAβ levels are significantly lower in 2- compared to 5-mo-old rats, as measured by quantitative immunoenzymatic histochemistry (Fig. 6A and SI Appendix, Fig. S2C).

Having established a lower iAβ-load in these young Tg animals, we assessed whether changes in the neuronal expression of IL-6 could also be detected at 2 mo of age. Following neuron-specific fluorescence quantification, levels of IL-6 were found to be up-regulated within the subiculum, but unchanged in CA1 of 2-mo-old Tg rats when compared with controls (Fig. 6B). Microglial cells were also normally distributed throughout the hippocampus, as the number of neuron-proximal microglia in the subiculum and CA1 were similar between the two groups (Fig. 6C).

Our results show that, during the initial stage of the amyloid pathology, iAβ levels are sufficient to provoke the neuronal expression of cytotoxic IL-6 in certain disease-vulnerable brain regions, but not sufficient to induce microglial migration. Thus, it is likely that iAβ levels must reach a biological threshold to induce a neuron-driven inflammatory cascade.

Expression of CCL2 in the Human Medial Temporal Lobe Shifts from Neurons to Glia with Advancing Aβ Pathology. Our findings in an AD Tg rat model indicated that Aβ-burdened neurons, rather than glia, produce potent inflammatory mediators well before initial plaque deposition. Although the McGill-R-Thy1-APP rat is a valuable model for understanding the inflammatory effects that are specific to iAβ, it does not fully reflect the neuropathological environment of the human central nervous system (CNS). Given that progressive iAβ accumulation has also been observed in the human brain (11–15, 40), we posited that Aβ-burdened neurons may produce a similar, plaque-independent inflammatory signal within the human entorhinal cortex and
Fig. 4. Microglia are recruited toward Aβ-burdened neurons and exhibit activated morphology in the absence of extracellular plaques. (A) To measure changes in microglial mobilization in the context of Aβ pathology, the number of Iba1-immunopositive cells (brown) within 50 μm of the subiculum and CA1 (indicated with boxes) were manually counted. NeuN was used as a marker of mature neurons (blue). Statistical analysis revealed a significant increase in the number of Iba1-IR cells in proximity or in direct contact with Aβ-burdened neurons in 5-mo-old Tg rats. In contrast, the total number of microglia within the hippocampus, as well as the total Iba1-IR percent-area were comparable between WT and Tg animals. Microglia from Tg rats also displayed morphological changes consistent with a proinflammatory phenotype, as revealed by an increase in dimensional ratio (n = 8 per genotype; *P < 0.05; **P < 0.01). (Scale bars, 100 μm.) (B) Pearson correlation analysis revealed that the number of neuron-proximal microglia was positively correlated with the abundance of neuronal CCL2 protein in CA1 of the hippocampus. In addition, microglia dimensional ratio was positively correlated with levels of neuronal IL-6 (n = 7 to 8 per genotype).

Hipposcrampus. We therefore compared the cell-specific expression of CCL2 in the human medial temporal lobe of subjects with and without extracellular plaques. For these purposes, we analyzed a collection of extremely well-preserved brain tissue obtained with short postmortem delay (2 to 4 h for all cases) and processed by perfusion-fixation. Such high-quality postmortem material is ideal for detecting subtle differences in the cell-specific expression of cytokines in the context of an evolving Aβ pathology.

All subjects analyzed were between 66 and 77 y of age at the time of death. Control subjects died of causes unrelated to neurological disease and did not exhibit cognitive or movement alterations. Minimal AT8-IR tau was restricted to the entorhinal cortex (Braak stages 0–1). TDP-43 pathology in the form of neuronal cytoplasmic inclusions and dystrophic neurites was only observed in one subject with diagnosed AD. None of the cases exhibited motor neuron damage or Lewy body pathology.

First, we used the monoclonal antibody, McSA1, targeting the N-terminal amino acids 1 to 12 of human Aβ to evaluate the extent of Aβ accumulation in postmortem brains of nondemented and AD subjects. We have previously shown by peptide preadsorption and superresolution structured illumination microscopy that McSA1 is highly specific for human Aβ and does not cross-react with the APP holoprotein or its cleavage products (15, 29, 41). In control cases, we found that all neurons exhibited substantial Aβ material (Fig. 7A). One subject with diagnosed AD displayed advanced plaque deposition throughout layers III–VI of the entorhinal cortex and all regions of the hippocampus, while McSA1-IR neurons were sparse and difficult to visualize, likely due to extensive plaque pathology and advanced neurodegeneration.

Next, we used the same anti-CCL2 monoclonal antibody utilized for animal experiments to analyze the cell-specific expression of CCL2 in these samples. In control subjects devoid of extracellular plaques, CCL2-IR was observed in all neurons of the entorhinal cortex, subiculum, and CA1 (Fig. 7B and C). Adjacent glia could also be detected but exhibited only faint immunolabeling (Fig. 7D).

Interestingly, glia displayed more intense CCL2-IR in subjects with extracellular plaques. While Aβ-burdened neurons appeared to remain the predominant source of CCL2 within these brain regions, a progressive shift toward increased glial CCL2 became apparent as insoluble plaque pathology developed.

The cell-specific expression of CCL2 within the AD brain with abundant plaques was notably different from that observed in control samples: While CCL2-IR neurons could still be clearly visualized, CCL2-IR became much more pronounced throughout glial cell bodies and extending processes (Fig. 7D). Our findings in the human brain reflect those obtained from our AD-like Tg rat model: In the absence of extracellular plaques, Aβ-burdened neurons represent the predominant source of CCL2.
within AD-vulnerable brain regions, while advanced plaque deposition and neurodegeneration is likely associated with a shift toward a glial immune response. These observations reinforce the duality of the role of neuroinflammation in early versus late pathological stages of AD.

Discussion
In the present study, we show that neurons participate in Aβ-driven neuroinflammation during the earliest stages of the amyloid pathology. By targeting and extracting specific populations of hippocampal neurons from preplaque APP Tg rats, we demonstrate that iAβ accumulation is sufficient to induce neuronal inflammatory signaling and microglial recruitment, months before initial plaque deposition and independent of cell death. Quantitative gene expression and IHC analyses revealed that these neurons generate a variety of potent chemotactic and proinflammatory molecules—including CCL2, CCL3, CSF-1, and IL-6—most of which are only detected in low quantities in microglia and astroglia at this early time-point.

With the recent discovery of immune-related genetic loci associated with increased AD risk (42, 43), research efforts have shifted toward understanding how microglia initiate and propagate neuroinflammation during AD with little regard for other major cell types within the brain. Experimental measures of neuroinflammation are most often attributed to changes in microglial activation, even though analytes assessed in whole-tissue samples are derived from a composite of cell-types, including neurons, astrocytes, oligodendrocytes, and components of the neurovascular unit. Although microglia are classically regarded as the primary immune cells within the CNS, they are not the sole effectors of neuroinflammation. As an example, astrocytes adopt a neurotoxic “A1” phenotype and lose critical neurotrophic functions following exposure to proinflammatory molecules and complement factors (44). Evidence also supports the potential role of oligodendrocytes in regulating immune responses in demyelinating diseases, such as multiple sclerosis, through the expression of cytokines and chemokines (45). Exposure of “eat me” molecules at the cell surface of neurons harboring toxic tau inclusions represents another mechanism by which nonmicroglial cells can stimulate the brain’s immune system (46).

Previous attempts have been made to characterize the AD neuronal transcriptome from microdissected samples recovered from archival postmortem brain material; however, as a result of long-term tissue fixation and storage conditions, techniques commonly used to measure differential gene expression, such as microarrays, RNA-seq, and mass spectrometry, can only detect robust transcriptional changes. Consequently, it is unlikely that low-abundant inflammatory transcripts could be detected or quantified from only a few-hundred cells, as is typically reported (47–51). In the present study, we employed LCM to extract thousands of pyramidal neurons from disease-relevant brain regions from flash-frozen tissue, allowing us to produce an enriched sample of

Fig. 5. Inflammatory mediators are up-regulated in Aβ-burdened neurons of preplaque Tg rats, but not in neighboring glial cells. Inflammatory mediators found to be up-regulated in Aβ-burdened neurons were probed by IHC (red), along with cell-specific markers, Iba1 (A) and GFAP (B), to identify brain macrophages and astrocytes, respectively (green). In 5-mo-old Tg animals, most cytokine-IR was observed within neurons of the hippocampus. No colocalization was found between glial cells and any of the inflammatory factors analyzed at this early pathological stage. (Scale bars, 50 μm.) (C) Using fluorescent oligonucleotide probes (red), CCL2 transcripts appeared to be more abundant within neurons of the hippocampus compared with neighboring glial cells (indicated by white arrowheads), which were distinguishable based on their characteristic DAPI staining (blue). (Scale bars, 20 μm.)
neurons bearing the highest quantity of intracellular Aβ. By performing target-specific amplification and quantitative gene-expression analysis using a PCR array specially designed to detect low-abundant inflammatory transcripts from low-yield samples, such as those produced by LCM, we successfully characterized the inflammatory profile of Aβ-burdened neurons, the results of which were validated by quantitative IHC and RNA FISH.

Each molecule up-regulated in Aβ-burdened neurons has also been shown to be expressed by neurons in the healthy and AD brain (52–55). In fact, several studies have demonstrated that levels of CCL2 and IL-6 are increased in the brains of patients with mild cognitive impairment (MCI) and AD (56–58), with one study suggesting that neurons exhibit the most pronounced increase in CCL2- and IL-6 when analyzed by IHC (54).

CCL2 in particular has been repeatedly implicated in early disease development. Although little is known about the pre-plaque neuroinflammatory environment, two independent studies have shown that CCL2 is increased in both brain and plasma of young, preplaque 3xTg mice with substantial Aβ accumulation (37, 59). Similarly, CCL2 has been found to be up-regulated in cerebrospinal fluid (CSF) and blood plasma of patients with MCI and AD (56–58), with one study reporting that neurons exhibit the most pronounced increase in CCL2 and IL-6 when analyzed by IHC (54).

CCL2 expression is markedly increased in glial cells, indicating a shift in cell-specific responses. Our findings underscore the fact that different cell-types variably contribute to CNS inflammation during AD.

CCL3 and CSF-1 expression are also altered in the context of AD. For example, levels of CCL3 in plasma are elevated in patients with higher neocortical Aβ burden, as determined by positron emission tomography (69). CSF-1 and other components of the CSF-1 signaling pathway are similarly up-regulated in the postmortem AD brain (58). Additionally, CSF-1 potentiates the proinflammatory effects of Aβ in hippocampal organotypic cultures, enhancing the release of CCL3 and IL-6 (70).

Surprisingly, Aβ-burdened neurons from preplaque Tg rats exhibited decreased expression of IL-12β, which is one of two components of the proinflammatory IL-12 heterodimer. Reports on the expression of IL-12 in humans and Tg mouse models of AD are limited and contradictory. One study has demonstrated that levels of IL-12 are decreased in the CSF of patients with AD compared with age-matched controls (71), while others have reported that levels of IL-12 are unchanged (72). It has also been shown that brain IL-12 is increased in two different Tg mouse models of AD; however, it is important to note that these studies were performed using animals with advanced plaque deposition, and measurements were conducted on either the full IL-12 heterodimer or the IL-12β subunit. To that point, other investigations profiling Aβ-associated neuroinflammation have demonstrated that, before extracellular plaque deposition, levels of IL-12α and IL-12 are in fact decreased in the brains of young Tg mice (37, 73). These data are consistent with the findings from our preplaque Tg rat model.

Coincident with the emergence of Aβ-mediated inflammation, we found that microglia adopt an activated morphological phenotype and become recruited toward the pyramidal
layer of the hippocampus. Under physiological conditions, “resting” microglia continuously patrol and survey their microenvironment through rapid extension and retraction of their processes (74, 75). In addition to these dynamic structural changes, microglia express a variety of surface receptors, allowing them to sample the neurochemical byproducts of both homeostatic and damage-associated processes (76). Accordingly, we found that, in the absence of extracellular plaques, Aβ-burdened neurons exhibited strong CCL2-IR throughout the entorhinal cortex. In contrast, glia appeared to represent the major CCL2-immunopositive cell-type within the AD brain. (Scale bars, 100 μm) (C) The cell-specific expression of CCL2 was consistent throughout all regions of the medial temporal lobe, including the subiculum (Sub) and region CA1. (Scale bars, 100 μm) (D) High-magnification micrographs revealed differential expression of CCL2 as a function of progressive Aβ pathology. In the absence of extracellular plaques, Aβ-burdened neurons appear to be the predominant source of CCL2 within the human medial temporal lobe, while established plaque pathology is associated with a progressive shift toward increased glial CCL2 expression (black arrowheads indicate CCL2-IR microglia). (Scale bars, 50 μm.)

Fig. 7. Aβ-burdened neurons are the predominant source of CCL2 in the human brain in the absence of extracellular plaques and pathological tau. (A) All neurons within the entorhinal cortex of nondemented subjects exhibited substantial intracellular Aβ accumulation, as revealed by McSA1 immunolabeling. One case with diagnosed AD exhibited advanced extracellular plaque pathology throughout the entorhinal cortex and medial temporal lobe, while McSA1-IR neurons were sparse and difficult to visualize. (Scale bars, 100 μm.) (B) Nondemented subjects devoid of extracellular plaques, Aβ-burdened neurons exhibited strong CCL2-IR throughout the entorhinal cortex. In contrast, glia appeared to represent the major CCL2-immunopositive cell-type within the AD brain. (Scale bars, 100 μm) (C) The cell-specific expression of CCL2 was consistent throughout all regions of the medial temporal lobe, including the subiculum (Sub) and region CA1. (Scale bars, 100 μm) (D) High-magnification micrographs revealed differential expression of CCL2 as a function of progressive Aβ pathology. In the absence of extracellular plaques, Aβ-burdened neurons appear to be the predominant source of CCL2 within the human medial temporal lobe, while established plaque pathology is associated with a progressive shift toward increased glial CCL2 expression (black arrowheads indicate CCL2-IR microglia). (Scale bars, 50 μm.)
dysfunction. However, it is also possible that iAβ-mediated cellular stress might precipitate the release of neuron-derived cues that mark an increased demand for glial trophic support. The nature of these neuronal interactions in our preplaque Tg rat model is, at present, unclear; however, they are likely time- and context-dependent. For example, CCL2 knockout or inhibition minimizes plaque pathology, diminishes inflammatory gene expression, and recovers cognitive performance in an AD Tg mouse model, but may have converse effects in otherwise WT animals (82, 83). In an experimental animal model of encephalitis, neuron-derived CCL2 promotes the recruitment of phagocytic macrophages and synaptic engulfment, resulting in significant motor deficits (84). In contrast, microglial contact at specialized neuronal somatic junctions likely protects against hypoxic injury, limiting lesion-size and cognitive impairment following stroke-induced ischemia (85). Similarly, it is unknown whether preplaque neuronal inflammatory signaling is harmful in aggravating cytotoxic damage, or beneficial in engaging immune trophic support during early stages of AD. Understanding how these complex neuronal interactions influence the brain’s immune system at varying stages of disease will ultimately inform on which molecular pathways may be most amenable to early therapeutic intervention.

Although the amyloid plaque represents a potent immunological structure within the brain, comprising an agglomerate of insoluble proteins, toxic cytokines, and complement factors, it is well-established that plaque-load is a poor correlate of cognitive decline, cell loss, and NFT density in disease-vulnerable brain regions (20, 86–91). Rather, compared with amyloid plaques, increasing levels of soluble Aβ are a better predictor of synaptic dysfunction, cognitive deficits, and pathological tau when analyzed in the postmortem AD brain (16, 18–20). We propose that the incremental build-up of soluble and oligomeric iAβ may provoke a neuron-specific immune reaction, setting off a neuroinflammatory cascade at the earliest stages of AD.

In sum, our findings reinforce the idea that the neuroinflammatory environment within the AD brain is complex, dynamic, and phase-dependent (8). We provide definitive evidence that the intracellular accumulation of Aβ is sufficient to trigger a neuron-derived inflammatory reaction, which is characterized by chemotactic signaling and mobilization of activated microglia toward the site of damage. Most importantly, we have shown that Aβ-loaded neurons act as “inflammatory agents” during the earliest stages of the amyloid pathology, and that this neuroinflammatory process is likely distinct from plaque-associated immune responses. Thus, the findings of our study have significant implications regarding the origin of the initial inflammatory reaction within the AD brain.

Materials and Methods

Animals and Brain Tissue Processing. McGill-R-Thy1-APP Tg rats express the human APP gene containing the Swedish and Indiana mutations under control of the murine Thy1.2 promoter. Male and female WT and homozygote Tg rats were housed in humidity- and temperature-controlled rooms under a 12-h light/dark cycle with access to food and water ad libidum. At 2 and 5 mo of age, rats were anesthetized with equithesin (pentobarbital based, 2.5 mL/kg, i.p. injection) followed by transcardiac perfusion with ice-cold 0.1 M phosphate buffer. All procedures were approved by the Animal Care Committee of McGill University and conform to the guidelines set out by the Canadian Council on Animal Care. Additional information on tissue processing can be found in SI Appendix.

Postmortem brain material was harvested and processed as previously described (15). Briefly, brains were removed 2 to 5 h postmortem and perfused via the internal carotid and vertebral arteries with physiological saline and fixative solution containing 4% PFA, 0.05% glutaraldehyde, and 0.2% picric acid. The medial temporal lobe was dissected and postfixed overnight in the same fixative solution without glutaraldehyde before being transferred to a sucrose solution, rendering optimal tissue preservation for microscopic analysis. Once received at McGill University, tissue blocks were cut into 40-μm-thick sections and stored in cryoprotectant at −20 °C.

Laser Capture Microdissection. Flash-frozen brain tissue from 5-mo-old WT and Tg rats was cut into 10-μm-thick sections using a Leica CM3050S cryostat. Tissue was thaw-mounted onto 1.0-mm PEN membrane-covered glass slides (MembraneSlide 1.0 PEN; Carl Zeiss), which were irradiated with UV light for 30 min prior to cryosectioning. Mounted tissue sections were stained with Cresyl violet, as described in SI Appendix.

The entire pyramidal layer of the subiculum and CA1 was microdissected from 40 tissue sections per animal using the PALM MicroBeam (Carl Zeiss). Neurons were identified based on their characteristic Cresyl violet staining: Neurons stained diffusely throughout the entire cell body, while glial cells exhibited darker staining exclusively within the nucleus. Microdissected neurons were pressure-catalyzed into 200-μL PCR tubes with opaque adhesive cap (AdhesiveCap 200 Opaque; Carl Zeiss) using the following method and settings: Cut energy, 75; cut focus, 70; auto-LPC dot-size, 12 (SI Appendix, Fig. S1A). mRNA extraction was performed immediately following LCM, as detailed in SI Appendix.

Brightfield and Fluorescent IHC. Detailed experimental protocols describing antibody dilutions and incubation times for immunostaining of both rat and human brain tissue can be found in SI Appendix.

Single-Molecule RNA FISH. Flash-frozen brain tissue was cryosectioned into 10-μm-thick slices, thaw-mounted onto standard glass microscope slides and stored at −80 °C until processed for RNA FISH. Sections were transfected directly from storage to 4% PFA for 15 min at 4 °C, and then processed according to the protocol provided by LGC Biosearch Technologies for Stellaris RNA FISH, as described in SI Appendix. A mixture of 25 CAL610-conjugated oligonucleotide probes, each 20 nucleotides in length, targeting rat CCL2 mRNA were designed using the online Stellaris Probe Designer (NCBI Reference Sequence: NM_031530.1). Confocal imaging was completed within 30 h.

Microscopy and Image Analysis.

Quantifying fluorescence intensity of neuronal cytokines. For each cytokine measured, two tissue sections from WT and Tg rats were immunolabeled as described in SI Appendix and imaged by confocal microscopy. Acquisition settings were held constant for all images being compared by quantitative analysis. One image containing the entirety of the subiculum and four to five images centered on the pyramidal layer of CA1 were acquired as 6-μm z-stacks using a 20× objective and converted to maximum intensity projections using Zen 202 SPS Black (Carl Zeiss).

To quantify fluorescence intensity of immunolabeled cytokines exclusively within neurons, confocal images were processed using Image/ software (National Institutes of Health). The channel corresponding to NeuN (green) was converted to a binary image using “Triangle” thresholding, and regions of interest (ROI) were defined as NeuN-immunopositive areas larger than 10 μm (SI Appendix, Fig. S2A). These ROI were then applied to the channel corresponding to the cytokine being measured (SI Appendix, Fig. S2A, red) and fluorescence intensity was quantified exclusively within those ROI.
Signal intensity of each image is expressed as the total ROI integrated density normalized by the total ROI area.

Quantitation of neuronal microglial recruitment and activation. To identify neurons and microglia within the hippocampus of WT and Tg rats, two tissue sections per animal were immunolabeled with anti-NeuN and -Iba1 antibodies, as described in SI Appendix.

To measure microglial mobilization toward Aβ-burdened neurons, one image containing the entirety of the subiculum and four images centered along the pyramidal layer of CA1 were acquired as 20x objective and processed using the “Extended Depth of Focus” function in Zeiss. Four focal depth stacks (Carl Zeiss) of fixed brain areas (Boxed area: 50 μm × 0.02 mm²) were manually centered on the pyramidal layer of the subiculum and CA1, encompassing Iba1-immunopositive cells within 50 μm of hippocampal neurons. The number of microglial cells was manually counted and expressed as a function of area (0.05 mm²).

To assess the extent of microglial activation, double-fluorescent immunolabeling was performed using the same primary antibodies, and z-stack projections were acquired by confocal microscopy. To calculate microglial dimensional ratio, which represents cell body-size proportional to process length, we first measured the total image area occupied by Iba1-IR (SI Appendix, Fig. S2B). Images were then converted to binary and skeletonized to measure the total length of microglial processes. The dimensional ratio of each image was calculated from: (Iba1-IR area)/Iba1-IR length.

Assessing cell-specific expression of CCL2 mRNA. To identify neurons and microglia within the hippocampus of WT and Tg rats, two tissue sections per animal were subjected to RNA FISH as described above. Images centered along the pyramidal layer of CA1 were acquired as 5-μm z-stacks using a 63x objective with 1.5x zoom, and then converted to maximum-intensity projections.

Quantifying chromogen intensity of neuronal McS1A-IR. To quantify the neuronal accumulation of Aβ peptides, the relative intensity of neuronal McS1A-IR was quantified. Three images centered on CA1 were acquired using a 20x objective, converted to grayscale and variably thresholded using ImageJ software. Chromatin density could be precisely delineated and manually selected as ROI (SI Appendix, Fig. S2C). The integrated density and area of all ROIs (i.e., CA1 pyramidal neurons) were measured and summed (Σ integrated density/area) to produce one value representing the total signal intensity for each image. Chromosome intensity was then quantified using the reciprocal intensity (1/r) method (15), whereby higher “r” values are associated with more intense chromosome staining, and thus higher protein levels.

Tissue sections were processed simultaneously to maintain identical immunolabeling and microglial reactivity, Pearson correlation coefficient (r) was measured. The sample size n for each experiment represents the number of animals tested. Each data point represents the average value of all technical replicates per animal. The final sample size is represented in all figures. Significance was set at P < 0.05 for all statistical tests.

Data Availability. Additional information on the data presented is available upon request.

ACKNOWLEDGMENTS. We thank Dr. Alfredo Ribeiro-da-Silva for allowing us to use the Axio Imager M2 widefield microscope and for his guidance and assistance in acquiring the images presented, and the McGill University Alzheimer’s disease and aging study for their help with laser-capture microdissection, and confocal microscopy. The A.C.C. laboratory is grateful for the unrestricted support received from Dr. Alan Frost, the Frost family, and Merck Canada. This research is supported by the Canadian Institutes of Health Research Project grant PTH-364544 (to A.C.C.) and 2017-1-1-NKP-2017-00002 (to the Human Brain Research Laboratory). L.A.W. is the recipient of a Doctoral Training Fellowship from the Fonds de recherche du Quebec-Sante. S.D.C. is the holder of the Charles E. Frost/Merck Research Associate position. J.C.M. was the recipient of a Rotary Foundation Global Grant Scholarship. A.C.C. is the holder of the McGill University Charles E. Frost/Merck Chair in Pharmacology and is a member of the Canadian Consortium on Neurodegeneration in Aging.
44. S. A. Liddelow, C. A. Waller, A. Ducatenzeiler, A. C. Cuello, Microglial processes contribute to microglial cross-talk in the central nervous system. J. Neuroinflammation 9, 62 (2012).

54. I. Heggland, I. St. Corkas, H. T. Soligard, A. Kobo-Flatoe, M. P. Witwer, Stereological estimation of neuron number and plaque load in the hippocampal region of a transgenic rat model of Alzheimer’s disease. Eur. J. Neurosci. 41, 1245–1262 (2015).

56. T. M. Heneka et al., Microglial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP(V717I) transgenic mice. J. Neuroinflammation 22, 2 (2015).

66. M. C. Janeski et al., Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemotactic protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J. Neuroinflammation 2, 23 (2005).

76. M. T. Ferretti, M. A. Bruno, A. Ducatenzeiler, W. L. Klein, A. C. Cuello, Intracerebral Alzheimer’s oligomers and early inflammation in a model of Alzheimer’s disease. Neurobiol. Aging 33, 1329–1342 (2012).

86. E. N. Wilson et al., Microdose lithium NP03 diminishes pre-plaque oxidative damage and neuroinflammation in a rat model of Alzheimer’s disease. Curr. Alzheimer Res. 15, 1220–1230 (2018).

96. M. A. Lynch, C. M. Refojo, multifaceted process of activated microglia. Mol. Neurobiol. 40, 139–156 (2009).

106. C. Mori et al., Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 15, 88–102 (2008).

116. M. M. Grant, A. Ducatenzeiler, M. Szyf, A. C. Cuello, Abeta immune-reactive material is present in several intracerebral compartments in transfected, neuronomically differentiated, P19 cells expressing the human amyloid beta-protein precursor. J. Alzheimers Dis. 2, 207–222 (2000).

126. L. Bertram, P. E. Tanzi, Alzheimer disease risk genes: 29 and counting. Nat. Rev. Neuro. 15, 191–192 (2019).

136. M. C. Karch, A. M. Goate, Alzheimer’s disease risk genes and mechanisms of disease pathobiology. Psychiatry 77, 43–51 (2015).

146. A. A. Liddelow et al., Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).

156. L. Peferoen, M. Kipp, P. van der Valk, J. M. van Noort, S. Amor, Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 141, 302–313 (2014).

166. J. Breistadt, A. M. Tolovsky, B. Ghetti, M. Goedert, M. G. Spillantini, Living neurons with tau filaments aberrantly express phosphorytideine and are phagocytosed by microglia. Cell Rep. 24, 1939–1948.e4 (2018).

176. E. S. Drummond, S. Nyakay, B. Uebereither, T. Wünsiewski, Proteomic analysis of neurons microdissected from formalin-fixed, paraffin-embedded Alzheimer’s disease brain tissue. Sci. Rep. 5, 15456 (2015).

186. D. S. Ginsberg, M. J. Aldrild, S. Che, Gene expression levels assessed by CA1 pyramidal neuronal and regional hippocampal dissections in Alzheimer’s disease. Neurobiol. Dis. 35, 99–107 (2010).

196. D. R. Ginsberg et al., Microarray analysis of hippocampal CA1 neurons implicate early endosomal dysfunction during Alzheimer’s disease progression. Biol. Psychiatry 68, 885–893 (2010).

206. D. C. Hondius et al., Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease. Alzheimers Dement. 12, 654–668 (2016).

216. W. S. Liang et al., Neuronal gene expression in non-demented individuals with intermediate Alzheimer’s disease neuropathology. Neurobiol. Aging. 41(3), 549–566 (2019).

226. D. S. Yan et al., Amyloid-beta peptide receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94, 5296–5301 (1997).

236. G. M. Murphy, Jr, F. Zhao, L. Yang, B. Cordell, Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer’s disease. Am. J. Pathol. 157, 895–904 (2000).

246. A. Sokolova et al., Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol. 19, 392–398 (2009).

256. M. Q. Xia, S. X. Qin, L. J. Wu, C. R. Mackay, B. T. Hyman, Immunohistochemical study of the beta-chemokine receptor CCR1 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am. J. Pathol. 153, 31–37 (1998).

266. L. Ho et al., Elevated plasma MCP-1 concentration following traumatic brain injury as a potential “predispensation” factor associated with an increased risk for subsequent development of Alzheimer’s disease. J. Alzheimers Dis. 31, 301–313 (2012).

276. K. Ishioka et al., Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatr. Clin. Neurosci. 51, 135–138 (1997).

286. A. Olmos-Alonso et al., Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 139, 891–907 (2016).